<DOC>
	<DOCNO>NCT00993421</DOCNO>
	<brief_summary>The purpose study determine LY377604 + sibutramine work well LY377604 sibutramine alone treatment obesity .</brief_summary>
	<brief_title>A Weight Loss Study Overweight Men Women</brief_title>
	<detailed_description />
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Weight Loss</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Sibutramine</mesh_term>
	<criteria>Are body mass index ( BMI ) 27 45 kg/m^2 , inclusive , time screen . Have Diastolic Blood Pressure ( DBP ) great 90 mm Hg le 55 mm Hg , and/or Systolic Blood Pressure ( SBP ) &gt; 140 mm Hg &lt; 90 mmHg , confirm least 1 repeat measurement . Subjects hypertension treat antihypertensive medication exclude blood pressure within prescribed limit treat excluded medication . Changes antihypertensive medication permit within 30 day prior randomization Previous history poorly control hypertension , ( , &gt; 160/100 hypertension require 2 drug control ) . Have pulse rate &gt; 90 bpm &lt; 50 bpm . Evidence history prior significant cardiovascular disease , coronary artery disease , cardiovascular surgery , significant valvular disease , heart failure , arrhythmia , sick sinus syndrome stroke . Current treatment Î²blockers , calcium channel blocker , digitalis glycoside ( example , digoxin , etc ) , clonidine . Recent treatment ( within 2 week prior randomization ) catecholaminedepleting drug ( reserpine tetrabenazine , monoamine oxidase inhibitor ( MAOIs ) . Current treatment serotonergic drug , selective serotonin reuptake inhibitor ( SSRI ) , drug serotonin , norepinephrine , dopamine reuptake inhibitor , `` triptan '' ergot therapy migraine nausea , serotoninreleasing agent . Treatment significant inhibitor Cytochrome P2D6 ( CYP2D6 ) , bupropion , fluoxetine , paroxetine , quinidine , duloxetine , amiodarone , cimetidine , chlorpheniramine , clomipramine , doxepin , haloperidol , methadone , mibefradil , ritonavir . Participants bronchospastic disease treat bronchodilator prescription nonprescription beta adrenergic agonist . Peripheral vascular disease History thyrotoxicosis History seizure ( except childhood febrile convulsion ) increase risk seizure ( example , history significant head trauma intracranial surgery ) . Have significant change weight , define gain loss least 4 kg ( 9 lb ) 90 day prior randomization Have bariatric surgery ( example , gastric band gastric bypass ) Have liposuction within 90 day prior randomization Have disease affect adipose mass distribution energy balance ( example , Cushing 's syndrome , uncontrolled hyper hypothyroidism ) . Have take 30 day prior randomization , medication , herbal product , nutritional supplement affect adipose mass distribution energy balance , glucocorticoid , antiretrovirals , atypical antipsychotic , lithium , valproic acid , lamotrigine , anticonvulsant , mirtazapine , bupropion , phentermine , sibutramine , orlistat , rimonabant , amphetamine , ephedracontaining supplement . Note : Medications small transient effect weight medication may affect weight independent adipose mass ( example , estrogens diuretic ) , may continue , may start , stop , change course study . Have diagnose eating disorder , anorexia , bulimia , binge eat disorder , nocturnal eating disorder . Have diabetes mellitus treat medication , type 2 diabetes mellitus manage diet exercise hemoglobin A1c ( HbA1C ) &gt; 7.0 % . Symptomatic cholelithiasis 90 day prior randomization . Any lifetime history suicide attempt . History major depressive disorder last 2 year lifetime history severe psychiatric disorder ( example , schizophrenia bipolar disorder ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>